R.PR
REGISTERED-PRINCIPAL REGISTER
02/22/2022
Back to search
Official data from USPTO
REZUROCK
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
02/22/2022
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
04/25/2019
Registration date
02/22/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/22/2022
Last transaction
02/22/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/17/2021
First use in commerce
08/17/2021
Drawing code
4
Owner type
16
Owner location
Warrendale, PA, US
Examiner
DUBOIS, MICHELLE
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Kadmon Pharmaceuticals, LLC
Representatives
Michael J. Leonard Fox Rothschild LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals and pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical products for the prevention and treatment of respiratory diseases
Publications
History of USPTO decisions and trademark events.
29 publications found
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/20/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/19/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/14/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/13/2021
IUAF
USE AMENDMENT FILED
09/02/2021
EISU
TEAS STATEMENT OF USE RECEIVED
09/02/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/22/2021
EX2G
SOU EXTENSION 2 GRANTED
04/20/2021
EXT2
SOU EXTENSION 2 FILED
04/20/2021
EEXT
SOU TEAS EXTENSION RECEIVED
04/20/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/23/2020
EX1G
SOU EXTENSION 1 GRANTED
10/21/2020
EXT1
SOU EXTENSION 1 FILED
10/21/2020
EEXT
SOU TEAS EXTENSION RECEIVED
10/21/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/21/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/25/2020
PUBO
PUBLISHED FOR OPPOSITION
02/25/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/05/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/23/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/16/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/15/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/15/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/16/2019
GNRT
NON-FINAL ACTION E-MAILED
07/16/2019
CNRT
NON-FINAL ACTION WRITTEN
07/16/2019
DOCK
ASSIGNED TO EXAMINER
07/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/10/2019
NWAP
NEW APPLICATION ENTERED
04/29/2019
Continuous trademark protection
Get notified about every new filing that threatens REZUROCK or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.